肺型粗球孢子菌病与多发性硬化症使用那他珠单抗相关。
Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
机构信息
Department of Neurology, Central Institute, Clínicas Hospital, University of São Paulo, São Paulo, Brazil.
Facid Devry Faculty of Medicine, Teresina, Brazil.
出版信息
Mult Scler. 2018 Jun;24(7):1002-1004. doi: 10.1177/1352458518763091. Epub 2018 Apr 13.
BACKGROUND
Natalizumab (NTZ) is a monoclonal antibody with an immunosuppressive effect that reduces the inflammation of the central nervous system, and it has been used for the treatment of relapsing-remitting multiple sclerosis (RRMS). In patients with low cellular immune response, systemic mycosis arising from endemic areas may occur.
RESULTS AND CONCLUSION
In this article, we will describe a case of paracoccidioidomycosis as a complication to treatment with NTZ in an RRMS patient.
背景
那他珠单抗（NTZ）是一种具有免疫抑制作用的单克隆抗体，可减轻中枢神经系统炎症，已用于治疗复发缓解型多发性硬化症（RRMS）。在细胞免疫应答较低的患者中，可能会发生来自地方性流行地区的系统性真菌病。
结果和结论
本文将描述 1 例 RRMS 患者在接受 NTZ 治疗过程中出现的副球孢子菌病并发症。
Zotero 插件